[go: up one dir, main page]

ES2332916T3 - Composiciones y metodo para el tratamiento de tumores. - Google Patents

Composiciones y metodo para el tratamiento de tumores. Download PDF

Info

Publication number
ES2332916T3
ES2332916T3 ES05024729T ES05024729T ES2332916T3 ES 2332916 T3 ES2332916 T3 ES 2332916T3 ES 05024729 T ES05024729 T ES 05024729T ES 05024729 T ES05024729 T ES 05024729T ES 2332916 T3 ES2332916 T3 ES 2332916T3
Authority
ES
Spain
Prior art keywords
amino acid
acid sequence
identity
polypeptide
signal peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES05024729T
Other languages
English (en)
Inventor
David Botstein
Audrey Goddard
Austin L Gurney
Victoria Smith
Colin K Watanabe
William I Wood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ES2332916T3 publication Critical patent/ES2332916T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Polipéptido PRO7422 aislado. (a) que tiene por lo menos un 80% de identidad en la secuencia de aminoácidos con la secuencia de aminoácidos mostrada en la figura 2; (b) que tiene por lo menos un 80% de identidad en la secuencia de aminoácidos con la secuencia de aminoácidos codificada por la secuencia codificante de longitud completa del ADN plasmídico depositado bajo el número de acceso de ATCC PTA-551; (c) que tiene por lo menos un 80% de identidad en la secuencia de aminoácidos con el polipéptido mostrado en la figura 2 que carece de su péptido señal asociado; (d) que tiene por lo menos un 80% de identidad en la secuencia de aminoácidos con el dominio extracelular del polipéptido mostrado en la figura 2, con su péptido señal asociado; o (e) que tiene por lo menos un 80% de identidad en la secuencia de aminoácidos con el dominio extracelular del polipéptido mostrado en la figura 2, que carece de su péptido señal asociado; cuyo polipéptido se sobreexpresa en el cáncer de pulmón.
ES05024729T 1999-06-09 2000-05-15 Composiciones y metodo para el tratamiento de tumores. Expired - Lifetime ES2332916T3 (es)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US13838599P 1999-06-09 1999-06-09
US14479099P 1999-07-20 1999-07-20
US14684399P 1999-08-03 1999-08-03
US14818899P 1999-08-10 1999-08-10
US14932099P 1999-08-17 1999-08-17
US14939699P 1999-08-17 1999-08-17
US14932799P 1999-08-17 1999-08-17
US15011499P 1999-08-20 1999-08-20
US15173499P 1999-08-31 1999-08-31
US15170099P 1999-08-31 1999-08-31

Publications (1)

Publication Number Publication Date
ES2332916T3 true ES2332916T3 (es) 2010-02-15

Family

ID=27581055

Family Applications (2)

Application Number Title Priority Date Filing Date
ES05024729T Expired - Lifetime ES2332916T3 (es) 1999-06-09 2000-05-15 Composiciones y metodo para el tratamiento de tumores.
ES06001196T Expired - Lifetime ES2331657T3 (es) 1999-06-09 2000-05-15 Metodos para el diagnostico de tumores.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES06001196T Expired - Lifetime ES2331657T3 (es) 1999-06-09 2000-05-15 Metodos para el diagnostico de tumores.

Country Status (8)

Country Link
EP (3) EP1185642A2 (es)
JP (5) JP2003501087A (es)
AT (2) ATE440109T1 (es)
AU (1) AU4851900A (es)
CA (1) CA2371434A1 (es)
DE (2) DE60042799D1 (es)
ES (2) ES2332916T3 (es)
WO (1) WO2000075317A2 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001034799A1 (en) * 1999-11-12 2001-05-17 Human Genome Sciences, Inc. 6 human secreted proteins
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
US6395511B1 (en) 1998-11-27 2002-05-28 Darwin Discovery, Ltd. Nucleic acids encoding a novel family of TGF-β binding proteins from humans
US6960651B2 (en) 1999-06-29 2005-11-01 Millennium Pharmaceuticals, Inc. TANGO 332 polypeptides
AU5619700A (en) * 1999-06-29 2001-01-31 Millennium Pharmaceuticals, Inc. Novel genes encoding proteins having diagnostic, preventive, therapeutic, and other uses
WO2001047957A2 (en) * 1999-12-29 2001-07-05 Zymogenetics, Inc. Human fgf-10- (kgf-2)-like protein zfgf-10
AU5056501A (en) * 2000-03-31 2001-10-08 Nobuyuki Itoh Fibroblast growth factor-like molecules and uses thereof
AU2001272482A1 (en) * 2000-06-19 2002-01-02 F.Hoffmann-La Roche Ag Osteolevin gene polymorphisms
WO2003073991A2 (en) * 2002-03-01 2003-09-12 Celltech R & D, Inc. Methods to increase or decrease bone density
AU2003221841A1 (en) 2002-04-03 2003-10-27 Celltech R And D, Inc. Association of polymorphisms in the sost gene region with bone mineral density
EA015166B1 (ru) 2003-06-16 2011-06-30 Ю-Си-Би Мэньюфэкчуринг, Инк. Иммуногенные пептиды склеростина (sost), индуцирующие образование специфических антител
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
SMT202000095T1 (it) 2010-05-14 2020-03-13 Amgen Inc Formulazioni di anticorpi anti-sclerostina ad alta concentrazione
US9133272B2 (en) 2011-03-01 2015-09-15 Amgen Inc. Bispecific binding agents
AU2012236962B2 (en) 2011-03-25 2017-05-11 Amgen Inc. Anti-sclerostin antibody crystals and formulations thereof
ES2667554T3 (es) 2011-08-04 2018-05-11 Amgen Inc. Método para el tratamiento de los defectos de espacio óseo
AU2012362898B2 (en) 2011-12-28 2017-11-09 Amgen, Inc. Method of treating alveolar bone loss through the use of anti-sclerostin antibodies
US9925260B2 (en) 2012-07-05 2018-03-27 Ucb Pharma S.A. Treatment for bone diseases
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
MA41142A (fr) 2014-12-12 2017-10-17 Amgen Inc Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
GB201604124D0 (en) 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
CN119241705A (zh) 2018-03-30 2025-01-03 安姆根有限公司 C末端抗体变体

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5411860A (en) * 1992-04-07 1995-05-02 The Johns Hopkins University Amplification of human MDM2 gene in human tumors
EP0654092B1 (en) * 1992-06-26 2003-09-10 The Trustees Of Princeton University Method for detecting pre-cancerous or cancerous cells using p90 and p53 antibodies or probes
WO1995026201A1 (en) * 1994-03-28 1995-10-05 La Jolla Cancer Research Foundation Brevican, a glial cell proteoglycan
US5635370A (en) * 1994-04-08 1997-06-03 Yale University DNA encoding BEHAB, a brain hyaluronan-binding protein, and recombinant expression systems for production of BEHAB polypeptides
WO1999014327A2 (en) * 1997-09-17 1999-03-25 Genentech, Inc. Genes amplified in tumours, antibodies against the proteins coded thereby, and their use in diagnosis and treatment of cancer
WO1998031800A2 (en) * 1997-01-21 1998-07-23 Human Genome Sciences, Inc. Human proteins
IL136055A0 (en) * 1997-11-25 2001-05-20 Genentech Inc Fibroblast growth factor -19
EP1049708A4 (en) * 1998-01-23 2002-09-04 Human Genome Sciences Inc METH1 AND METH2 POLYNUCLEOTIDES AND POLYPEPTIDES
AU5619700A (en) * 1999-06-29 2001-01-31 Millennium Pharmaceuticals, Inc. Novel genes encoding proteins having diagnostic, preventive, therapeutic, and other uses

Also Published As

Publication number Publication date
EP1185642A2 (en) 2002-03-13
EP1657256A3 (en) 2006-08-09
EP1657256A2 (en) 2006-05-17
DE60043125D1 (de) 2009-11-19
JP4260778B2 (ja) 2009-04-30
JP2003501087A (ja) 2003-01-14
DE60042799D1 (de) 2009-10-01
ES2331657T3 (es) 2010-01-12
ATE444971T1 (de) 2009-10-15
EP1683811A2 (en) 2006-07-26
EP1657256B1 (en) 2009-10-07
JP2005027667A (ja) 2005-02-03
JP2006006330A (ja) 2006-01-12
WO2000075317A3 (en) 2001-02-08
WO2000075317A2 (en) 2000-12-14
CA2371434A1 (en) 2000-12-14
EP1683811B1 (en) 2009-08-19
JP2006006332A (ja) 2006-01-12
JP2006006331A (ja) 2006-01-12
EP1683811A3 (en) 2006-10-11
ATE440109T1 (de) 2009-09-15
AU4851900A (en) 2000-12-28
JP4252501B2 (ja) 2009-04-08

Similar Documents

Publication Publication Date Title
ES2332916T3 (es) Composiciones y metodo para el tratamiento de tumores.
ES2525677T3 (es) Celulasas, genes que las codifican y usos de las mismas
CO6160304A2 (es) Composiciones y metodos para el diagnostico y el tratamiento de tumores
TR200100056T2 (tr) Nörotrofik faktörler
ES2218872T3 (es) Polipeptido 10 de tipo citoquina de mamifero.
AR096027A2 (es) Proteínas insecticidas quiméricas de bacillus thuringiensis
ES2077666T3 (es) Proteina de union a fibronectina y su preparacion.
AU4778101A (en) Novel polypeptides, and nucleic acids encoding the same
ATE223488T1 (de) Gereinigte polyporus laccasen und dafür kodierende nukleinsäuren
NZ335485A (en) Isolated nucleic acid molecule encoding cancer associated antigen, the antigen itself, and uses thereof
IL195812A0 (en) Human tslp dna and polypeptides
DE3586853D1 (de) Immunologisch aktive peptide, geeignet zur einfuehrung von immunisierung gegen malaria und deren kodierung von genen.
ZA835963B (en) Molecular cloning and characterization of a gene sequence coding for human relaxin
ES2076976T3 (es) Metodo para detectar carcinomas de celulas pequeñas y utilizacion de secuencias que codifican acil-peptido hidrolasa para el mismo.
ES2663242T3 (es) Productos génicos expresados de forma diferencial en tumores y su utilización
BR9510067A (pt) Peptídio capaz de interagir com o domínio sh3 da proteína gap anticorpo ou fragmento de anticorpo dirigido contra um polipeptídeo sequência nucleotídica codificando para um polipeptídio ácido nucléico anti-sentido capaz de inibir ao menos parcialmente a produção de polipeptídeos sua utilização composição farmacêutica e utilização de um anticorpo ou fragmento de anticorpo
DE69120390D1 (de) Kollagen-bindendes protein sowie dessen herstellung
AUPP627498A0 (en) Novel peptides - i
CO4480058A1 (es) Genes codificantes y procedimiento de expresion de una nueva enzima: ftalil amidasa
DK0773999T3 (da) OR-1, en orphan-receptor tilhørende kernereceptorfamilien
AR012744A1 (es) Molecula de acido nucleico que codifica una proteina vinculadora de sucrosa, proteina vinculadora de sucrosa y metodo para producir una proteinavinculadora de sucrosa.
MXPA01004291A (es) Antigenos de chlamydia y fragmentos de acido desoxirribonucleico correspondientes y usos de los mismos.
PE34296A1 (es) Procedimiento para expresion extra-celular de proteina
PE20399A1 (es) Muteina ob
ATE303444T1 (de) Nukleinsäuren kodierend für das tmk gen